申请人:LEAD PHARMA HOLDING B.V.
公开号:US20180141909A1
公开(公告)日:2018-05-24
Novel compounds according to Formula I
Meta or para or a pharmaceutically acceptable salt thereof wherein:
A
11
-A
14
are N or CR
11
, CR
12
, CR
13
, CR
14
, respectively, with the proviso that no more than two of the four positions A in A
11
-A
14
can be simultaneously N; A
6
, A
7
, A
8
, A
9
, A
10
are N or CR
6
, CR
7
, CR
8
, CR
9
, CR
10
, respectively, with the proviso that at least one but no more than two of the five positions A in A
6
, A
7
, A
8
, A
9
, A
10
is N; R
1
is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R
5
is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with R
1
is represented by one of R
7
, R
8
or R
9
; R
15
is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and R
16
is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.